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ABSTRACT
Background and aims: The transcription factor nuclear
factor kappa B (NF-kB) has risen as a promising target for
anti-inflammatory therapeutics. In the liver, however, NF-
kB inhibition mediates both damaging and protective
effects. The outcome is deemed to depend on the liver
cell type addressed. Recent gene knock-out studies
focused on the role of NF-kB in hepatocytes, whereas the
role of NF-kB in Kupffer cells has not yet been
investigated in vivo. Here we present a novel approach,
which may be suitable for clinical application, to
selectively target NF-kB in Kupffer cells and analyse the
effects in experimental models of liver injury.
Methods: NF-kB inhibiting decoy oligodeoxynucleotides
were loaded upon gelatin nanoparticles (D-NPs) and their
in vivo distribution was determined by confocal micro-
scopy. Liver damage, NF-kB activity, cytokine levels and
apoptotic protein expression were evaluated after
lipopolysaccharide (LPS), D-galactosamine (GalN)/LPS, or
concanavalin A (ConA) challenge and partial warm
ischaemia and subsequent reperfusion, respectively.
Results: D-NPs were selectively taken up by Kupffer cells
and inhibited NF-kB activation. Inhibition of NF-kB in
Kupffer cells improved survival and reduced liver injury
after GalN/LPS as well as after ConA challenge. While
anti-apoptotic protein expression in liver tissue was not
reduced, pro-apoptotic players such as cJun N-terminal
kinase (JNK) were inhibited. In contrast, selective
inhibition of NF-kB augmented reperfusion injury.
Conclusions: NF-kB inhibiting decoy oligodeoxynucleo-
tide-loaded gelatin nanoparticles is a novel tool to
selectively inhibit NF-kB activation in Kupffer cells in vivo.
Thus, liver injury can be reduced in experimental fulminant
hepatitis, but increased at ischaemia–reperfusion.
The redox-sensitive transcription factor nuclear
factor kappa B (NF-kB) displays pleiotropic effects
during inflammation, immune response, cell survi-
val and proliferation and is a major target of novel
drugs counteracting the inflammatory response.1 2
In the liver, however, NF-kB is thought to exhibit a
dual role, depending on the cell type. Activation of
NF-kB in the resident liver macrophages, ie,
Kupffer cells (KCs), causes increased expression of
proinflammatory cytokines leading to inflamma-
tion and liver failure.3 Induction of NF-kB activity
in hepatocytes, however, is linked to cellular
protection by increasing the transcription of anti-
apoptotic genes.4 Most studies addressing this
point have been performed with isolated liver cells
in vitro.
Recent publications tried to shed some light on
this issue in vivo.5–8 Since constitutive NF-kB
knock-out mice die during embryogenesis,9 an
approach guided by the creation of conditional
knock-out animals was pursued. NF-kB is mainly
activated upstream by a kinase complex containing
the (catalytic) subunits I-kappaB kinase a (IKKa),
IKKb and the regulatory protein NF-kB essential
modulator (NEMO).10 11 Hepatocyte-specific
NEMO deletion leads to a complete inactivation
of NF-kB, which correlates with enhanced suscept-
ibility to tumour necrosis factor a (TNFa) stimula-
tion, ischaemia–reperfusion injury5 and, finally, to
cancer development.6 Hepatocyte-specific p65
knock-out mice are also more susceptible to
TNFa-induced liver damage.7 IKKb knock-out in
hepatocytes does not abolish NF-kB activation
entirely, hence a protection of the parenchyma to a
certain degree upon TNFa challenge still remains.8
To our knowledge, conditional NF-kB knock-out
mice for KCs are not available, and a genetic
approach to inhibit NF-kB in KCs would not easily
be suitable for clinical application. Moreover,
adenoviral transfection of an IkB super-repressor
is not limited to KCs,12 and liposomal targeting of
the liver macrophages with NF-kB inhibiting decoy
oligodeoxynucleotides cannot ensure an exclusive
transport to KCs only.13
Therefore, aims of this study were (1) to develop
a non-genetic approach to selectively abrogate NF-
kB activation in KCs without interfering with NF-
kB activity in hepatocytes, and (2) to subsequently
elucidate the role of NF-kB activation in KCs in
different settings of hepatic inflammatory injury.
Here we report a novel Kupffer cell specific
carrier based on gelatin nanoparticles (NPs), which
enables selective delivery of NF-kB decoy oligo-
deoxynucleotides to KCs without affecting NF-kB
in hepatocytes. NF-kB decoy oligodeoxynucleo-
tides are double-stranded oligonucleotides which
lead to competitive cis–trans interactions between
oligonucleotides and the transcription factor, thus
preventing binding of NF-kB to the designated
DNA.14 15
In a model of D-galactosamine/lipopolysacchar-
ide (GalN/LPS)-induced as well as concanavalin A
(ConA)-induced hepatic failure, treatment with
NF-kB D-NPs reduced liver injury markedly.
Interestingly, NF-kB activation in KCs seems to
possess a different role in the setting of warm
hepatic ischaemia–reperfusion injury, since here
selective inhibition led to an increase of liver
damage.
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MATERIALS AND METHODS
Decoy oligodeoxynucleotides
NF-kB decoy oligodeoxynucleotides (59-AGT TGA GGG GAC
TTT CCC AGG C-39, 59-GCC TGG GAA AGT CCC CTC AAC
T-39) and scrambled NF-kB decoy oligodeoxynucleotides (59-
CCT TGT ACC ATT GTT AGC C-39, 59-GGC TAA CAA TGG
TAC AAG G9) have been described elsewhere16 17 and were
purchased from Biomers, Ulm, Germany (biomers.net).
Consensus sequences for p50 and p65 are underlined. For
improved stability, all oligodeoxynucleotides were bridged with
a phosphorothioate (PTO) backbone.18 For biodistribution
studies, cis-decoy oligodeoxynucleotides were 59-end-labelled
with Alexa Fluor 488 fluorescent dye.
Preparation of oligonucleotide-loaded gelatin nanoparticles
Gelatin NPs were prepared as described previously by Zillies and
Coester.19 NPs were incubated with a solution containing NF-kB
decoy ODN, scrambled decoy ODN or Alexa Fluor 488-labelled
NF-kB decoy ODN respectively. D-NP suspensions were freeze-
dried and finally rehydrated under iso-osmotic conditions.
Animals
Male Sprague–Dawley rats (190–220 g) were purchased from
Charles River laboratories (Sulzfeld, Germany). C57Bl/6 mice
(20–25 g) were obtained from the animal facilities of the
Institute of Experimental and Clinical Pharmacology and
Toxicology of the University of Erlangen–Nuremberg,
Germany. They were maintained under controlled conditions
(22uC, 55% humidity and 12 h day/night rhythm) and fed a
standard laboratory chow.
Experimental model for distribution studies in rats
One millilitre of buffered NP solution containing 20 nmol Alexa
Fluor 488 59-end-labelled NF-kB decoy oligonucleotides was
injected into the portal vein and the organs were removed after
15 min. Livers were drained, rinsed free of blood with PBS and
perfused with formalin 3% in PBS for protein fixation.
Experimental model of NF-kB induction by LPS in rats
One millilitre of either 20 nmol NF-kB D-NP solution or
scrambled D-NP solution was injected into the portal vein.
After 15 min, 10 mg of LPS (50 mg/ml in PBS, Escherichia coli
serotype 055:B05; Sigma, Munich, Germany) was applied to the
portal vein. After 30 min blood and organs were collected.
Mice model of fulminant hepatic failure
GalN (Roth, Karlsruhe, Germany) was administered i.p. at
700 mg/kg 30 min prior to lipopolysaccharide (LPS, Salmonella
abortus equi, i.p., 4.5 mg/kg; Sigma-Aldrich Chemie, Taufkirchen,
Germany).20 ConA (Sigma-Aldrich Chemie) was applied intra-
venously at 20 mg/kg. Mice were treated (i.v.) with 150 ml of a
3 nmol NF-kB D-NPs or scrambled D-NPs per mouse 20 min
prior to GalN administration or 2 h prior to ConA administra-
tion. In another set of experiments NF-kB NPs or scrambled
Figure 1 Distribution of decoy
oligonucleotide-loaded gelatin
nanoparticles (D-NPs) in rat organs. (A)
Rat organs (15 min after D-NP
application) were sliced and stained. Red:
Alexa Fluor 488 end-labelled nuclear
factor kappa B (NF-kB) decoy
oligonucleotides (ODNs). Blue: Hoechst
staining of nuclei. Green: macrophage
specific CD 163. Co-localisation of
macrophages and NF-kB decoy ODNs are
indicated by the yellow colour. (B)
Analysis of liver sections. Red: Alexa
Fluor 488 end-labelled NF-kB decoy
ODNs. Green: Kupffer cells (KCs) specific
CD 163. Blue: Hoechst staining of nuclei.
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D-NPs were given 2 h after GalN/LPS injection. Twenty
animals per group were used to determine survival rate.
Rat model of partial warm hepatic ischaemia–reperfusion injury
The model used has been described by us before.21 The arterial
and portal blood flow to the left lateral and median lobe of the
liver was interrupted by applying an atraumatic clip, resulting
in a 70% liver ischaemia. After 1 h of ischaemia, the blood
supply was restored by removal of the clip and the reperfusion
period was initiated. Blood samples were collected into
heparinised tubes and animals were sacrificed after 2 and 24 h
of reperfusion, respectively.
Fifteen minutes prior to initiation of ischaemia, 1.0 ml of
either 20 nmol NF-kB D-NP solution or scrambled D-NP
solution, respectively, were injected into the portal vein over a
period of 5 min.
Histology of rat liver tissue
Formalin-fixed, paraffin embedded rat liver samples were cut
into 8 mm slices. After deparaffinisation/rehydration, slices were
stained using Coverplate chambers (Thermo Shandon,
Frankfurt, Germany). For evaluation of NF-kB activation,
sections were incubated with a rabbit polyclonal p65-antibody
(1:50; RB-9034; Labvision, Fremont, California, USA) and a
mouse anti-rat monoclonal CD 163-antibody (1:100;
MCA342R; AbD Serotec, Duesseldorf, Germany) overnight at
4uC. The secondary antibodies Alexa Fluor 488 goat–anti-mouse
and Alexa Fluor 546 goat–anti-rabbit (Invitrogen, Karlsruhe,
Figure 2 Lipopolysaccharide (LPS)-
induced hepatic nuclear factor kappa B
(NF-kB) activation/translocation and
tumour necrosis factor a (TNFa) mRNA
expression is reduced by application of
decoy oligonucleotide-loaded gelatin
nanoparticles (D-NPs). (A) NF-kB binding
activity was determined by
electromobility shift assay (EMSA) of
whole rat liver homogenates. One
representative shift out of three is shown
(upper panel). Lower panel shows the
relative light unit (RLU) density. Controls
were defined as 1.0 (n = 3, mean with
the SEM), *p,0.05 vs scr. D-NPs). (B)
Rat liver slices stained with an antibody
against p65, shows p65 distribution in
Kupffer cells. Red: p65. Green: Kupffer
cells. Blue: Hoechst staining of nuclei.
(C) p65 staining of rat liver slices in lower
magnification shows p65 distribution in
hepatocytes (arrows). Red: p65. Green:
Kupffer cells. Blue: Hoechst staining of
nuclei. (D) TNFa mRNA expression of rat
liver homogenates, controls were defined
as 1.0 (n>5, mean with the SEM,
*p,0.05 vs scr. D-NPs). scr., scramble.
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Germany) were applied for 45 min, followed by staining of
nuclei with Hoechst. Sections were mounted with PermaFluor
Mounting Medium (Beckmann Coulter, Krefeld, Germany) and
analysed by confocal laser scanning microscopy (CLSM) (Zeiss
LSM 510 Meta CLSM; Carl Zeiss Microscope Systems, Jena,
Germany). For evaluation of nanoparticle biodistribution, slices
were treated accordingly (primary antibody mouse–anti-rat
monoclonal CD 163, AbD Serotec, and secondary antibody
Alexa Fluor 633 goat–anti-mouse, Invitrogen).
For evaluation of effects of decoy-nanoparticles on tissue
damage, leucocyte infiltration and apoptosis after ischaemia–
reperfusion, formalin-fixed liver tissue samples were embedded
in paraffin. Sections (5 mm thickness) were cut and stained with
haematoxylin and eosin (HE) using a standard protocol, with
the terminal desoxynucleotide transferase-mediated dUTP nick
end labelling (TUNEL) assay according to the manufacturer’s
instructions (ApopTag Peroxidase In Situ Apoptosis Detection
Kit; Intergen, Purchase, New York, USA) and with naphthol
ASD chloroacetate (ASD) in order to stain granulocytes.
The histological evaluations were done in a blinded fashion
and a Leitz Laborlux S microscope (Leica Microsystems,
Wetzlar, Germany) was used. In HE-stained sections the extent
of necrosis (comprising loss of architecture, karyolysis and cell
swelling) was expressed as a percentage. The number of ASD-
stained granulocytes in the periphery of the necrosis was
counted in 10 high-power fields (HPFs). Apoptotic hepatocytes
Figure 3 Reduction of nuclear factor
kappa B (NF-kB) activity by
oligonucleotide-loaded gelatin
nanoparticles (D-NPs) leads to a
significant decrease in liver injury after
7 h D-galactosamine/lipopolysaccharide
(GalN/LPS) challenge and correlates with
extent of NF-kB activation in Kupffer cells
(KCs). (A) Transaminase levels (aspartate
transaminase (AST) and alanine
aminotransferase (ALT)) of mice (n = 3,
mean with the SEM, *p,0.05 vs scr. D-
NPs). (B) Representative haematoxylin–
eosin staining of mice liver sections.
(C) NF-kB binding activity was
determined by electromobility shift assay
(EMSA) of whole mice liver
homogenates. One representative shift
(out of three) is shown and the mean
relative light unit (RLU) density is shown
on the right panel. Controls were defined
as 1.0 (n = 3, meanwith the SEM,
*p,0.05 vs scr. D-NPs). (D) Plasma level
of tumour necrosis factor a (TNFa) and
interleukin 6 (IL6) in mice were
determined by enzyme-linked
immunosorbent assay (ELISA) (n = 3,
mean with the SEM, *p,0.05 vs scr.
D-NP). scr., scramble.
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were counted in 20 HPFs and were identified by staining with
the TUNEL assay in combination with morphological features
as chromatin condensation, forming of apoptotic bodies and cell
shrinkage.
DNA binding of NF-kB
Electromobility shift assays (EMSAs) were performed as
described previously.22 The consensus binding-sequence for
NF-kB was 59-AGT TGA GGG GAC TTT CCC AGG C-39
(Promega, Mannheim, Germany). Relative light unit (RLU)
density was determined by autoradiography using the Cyclone
Phosphor Imager (Perkin Elmer, Dreieich, Germany).
Analysis of TNFa mRNA expression
mRNA from liver tissue (25 mg) was isolated using the RNEasy
Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was
carried out using the High Capacity cDNA Reverse
Transcription Kit. Real time PCR was conducted with the
TaqMan Universal Master Mix Kit in a 7300 Real-Time PCR
System (all from Applied Biosystems, Hamburg, Germany).
TNFa primers and probe (Rn99999017_m1) were also
obtained from Applied Biosystems. Glyceraldehyde-3-phosphate
dehydrogenase GAPDH) primers were designed using the Primer
Express 2.0 software program. GAPDH forward primer: 59-GGG
AAG GTG AAG GTC GGA GT-39; reverse primer: 59-TCC ACT
TTA CCA GAG TTA AAA GCA G-39; probe: 59-ACC AGG
CGC CCA ATA CGA CCA A-39.
Results were quantified based on the relative expression of the
TNFa gene versus the housekeeping gene GAPDH using the
mathematical model for relative quantification according to Pfaffl.23
Measurement of transaminase activities
Activities of serum aminotransferases (ALT and AST) were
determined in heparinised serum 7 h after the induction of liver
injury using an automated procedure.
Haematoxylin–eosin staining of mice liver tissue
Morphology of formalin-fixed, paraffin-embedded samples of
the mice liver tissues was evaluated after H&E-staining (30 s
Mayer’s Haemalum (Merck, Darmstadt, Germany); 3 s DEPC-
treated water; 1 min 70% ethanol; 1 min 95% ethanol; 30 s
eosin Y (Sigma Chemical, Deisenhofen, Germany); 1 min 95%
ethanol; 1 min 95% ethanol; 1 min 100% ethanol; air-dry for at
least 10 min).
Cytokine measurement in murine plasma
Sandwich ELISAs for murine plasma TNFa and IL6 were
performed using flat-bottom high-binding polysterene microtitre
plates (Greiner, Nurtingen, Germany). Antibodies were purchased
from BD PharMingen Transduction Laboratories (Heidelberg,
Germany). Streptavidin–peroxidase (Jackson Immuno Research,
West Grove, Pennsylvania, USA) and the peroxidase chromogen
tetramethylbenzidine (Boehringer Mannheim, Mannheim,
Germany) were used according to the manufacturers’ instructions.
Cytokine measurement in rat plasma
Blood samples were taken after 24 h of post-ischaemic reperfu-
sion, heparinised and analysed with a Rat TNFa UltraSensitive
ELISA Kit (BioSoure, Camarillo, California, USA).
Western blot analysis
Western blot analysis were performed as described previously.22
Proteins transferred to the membrane were identified by
incubating with primary antibody (Bcl-xl; Santa Cruz,
Heidelberg, Germany; XIAP, JNK, pJNK, Cell Signaling,
Frankfurt, Germany; at 4uC, over night), followed by incubation
with a HRP-conjugated secondary antibody (goat anti rabbit,
Dianova, Hamburg, Germany). The reactive bands have been
visualised employing a chemiluminescent detection kit (ECL Plus,
Amersham Pharmacia, Uppsala, Sweden). b-Actin was used as
loading control (Millipore, Billerica, Massachusetts, USA).
Measurement of caspase-3 like activity
Liver tissue (20–60 mg) was homogenised (Potter S, B. Braun
Biotech) in 200–600 ml lysis buffer (25 mmol/l Hepes; 5 mmol/l
MgCl2; 1 mmol/l EGTA; pH 7.5). Protein quantification was
done by use of the Bradford assay.24 Extracts were incubated
with Ac-DEVD-AFC, and the generation of AFC was deter-
mined by fluorescence measurement (excitation: 385 nm;
emission: 505 nm).
Figure 4 Pro-apoptotic processes are reduced in mice treated with
oligonucleotide-loaded gelatin nanoparticles (D-NPs) before challenge
with D-galactosamine/lipopolysaccharide (GalN/LPS), whereas anti-
apoptotic protein expression is not diminished. (A) Hepatic expression of
jun N-terminal kinase (JNK), pJNK and b-actin, respectively, by western
blot analysis. One representative blot is shown. (B) Hepatic expression of
X-linked inhibitor of apoptosis protein (XIAP), Bcl-xl and b-actin,
respectively, by representative western blot analysis. (C) Caspase-3 like
activity assay, controls were defined as 1.0 (n = 3, mean with the SEM,
*p,0.05 vs scramble D-NPs).
Hepatology
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Statistical analysis
Animal experiments were performed using the number of
animals as shown in the respective figure legends. Results are
shown as mean with the SEM. Statistical analysis was
performed using the GraphPad Prism 3.03 software.
Significance (*) was calculated at a 95% confidence interval in
comparison to the corresponding control experiments (non-
parametic t test).
RESULTS
Persistent binding of NF-kB decoy oligonucleotides onto gelatin
nanoparticles of well-defined size diameter
Oligonucleotides (ODNs) were bound to gelatin NPs via ionic
interactions between the negatively charged DNA and the
positively modified surface of the NP.19 25 A supernatant of
decoy oligonucleotide-loaded gelatin NPs (D-NPs) suspension
was analysed spectrophotometrically after various times to
ensure persistent attachment of NF-kB decoy oligonucleotides.
D-NPs displayed an average size of 262.5 nm with a poly-
dispersity index of 0.105, which indicates the homogenous size
distribution of particles.19 25
Intraportal injection of NF-kB gelatin nanoparticles results in
predominant uptake by hepatic Kupffer cells
Upon intravenous administration, NPs are generally cleared
from the circulation through phagocytosis, preferentially by
macrophages of the reticuloendothelial system (RES) concen-
trating mainly in liver and spleen.26 Due to their well-defined
particle size distribution around 260 nm, solid, inflexible gelatin
NPs are too large to pass through the endothelial fenestrae
(approx. 175 nm wide). Therefore, the uptake of gelatin NPs by
hepatocytes should be almost impossible since the parenchyma
is not accessible to these constructs.
Fifteen minutes after application of gelatin NPs loaded with
Alexa Fluor 488-labelled decoy oligonucleotides, the majority of
decoy oligonucleotides were distributed within the liver
referring to the number of positively stained cells. No detectable
fluorescence was found in the brain, the kidney or the heart,
and smaller quantities could be seen in lung and spleen (fig 1A).
Figure 1B displays the exact pattern of hepatic allocation, with a
distinguished uptake of decoy oligonucleotides by KCs.
Importantly, hepatocytes showed no incorporation of decoy
oligonucleotides.
NF-kB decoy oligonucleotide-loaded gelatin nanoparticles
reduce NF-kB activation and translocation in Kupffer cells
EMSA analysis (fig 2A) showed significantly reduced LPS
(30 min) evoked NF-kB DNA binding activity in liver tissue of
D-NP-treated animals in comparison to the use of non-binding
scrambled D-NP (1.45 (SD 0.47) and 6.62 (SD 1.31) x-fold
increase, ie, reduction to 21.9%). Moreover, nuclear transloca-
tion of p65, the most common subunit of NF-kB in the context
of inflammation, was inhibited in KC by the administration of
D-NPs (fig 2B). Whereas p65 was found within the nucleus after
scrambled D-NP administration upon LPS challenge (left panel)
the application of D-NP resulted in a cytoplasmatic retention of
p65 (right panel). Nuclear p65 translocation in hepatocytes after
30 min of LPS challenge was very rare and was not affected by
the application of D-NP (fig 2C, arrow).
To confirm that our D-NPs in fact inhibit NF-kB driven
transcription, we measured the expression of the TNFa gene. D-
NP markedly attenuated TNFa expression, whereas scrambled
D-NPs had no effect (51.45 (SD 20.23) vs 81.52 (SD 21.09) x-fold
increase, ie, reduction to 63.1%; fig 2D). The discrepancy
between the extent of NF-kB inhibition and TNFa reduction
might reflect the fact that TNFa underlies additional regulatory
mechanisms besides the NF-kB system.
GalN/LPS-induced liver injury is reduced by NF-kB
oligonucleotide-loaded gelatin nanoparticles
The effect of D-NPs was tested in a widely accepted model of
fulminant hepatitis ie, in the model of GalN/LPS induced liver
injury. NF-kB D-NPs were injected 20 min before GalN/LPS
challenge. Liver injury was strongly reduced as determined by
measurement of serum transaminase activities 7 h after GalN/
LPS administration (fig 3A). The fact that serum transaminase
activities in NF-kB D-NP-treated animals after GalN/LPS
administration are within the range of those of control animals
suggests a lack of adverse effects of D-NPs to the liver.
Histological examination of liver tissue by H&E staining
revealed a complete preservation in liver structure of NF-kB D-
NP-treated animals (fig 3B). Furthermore, survival of animals
was significantly increased by treatment with NF-kB D-NPs,
scored 7 h after GalN/LPS challenge. Only one animal died in
the D-NP-treated group (n = 20) compared to eight animals in
the group that received scrambled D-NPs (n = 20) prior to
GalN/LPS stimulation (p,0.05).
Interestingly, injection of NF-kB D-NPs even 2 h after the
GalN/LPS administration seems to be beneficial with regard to
transaminase measurements. Alanine aminotransferase (ALT)
levels are significantly reduced in animals treated with NF-kB
D-NPs as compared to the scrambled D-NP (1230 (SD 136) vs
3110 (SD 880) U/l) whereas aspartate transaminase (AST) levels
only show a tendency of reduction in the NF-kB D-NP group as
compared to the scrambled D-NP group (1306 (SD 242) vs 1790
(SD 216) U/l).
As liver injury was diminished by NF-kB D-NPs, we next
evaluated the degree of NF-kB inhibition and subsequent NF-kB
dependent transcription. EMSA analysis clearly showed a
Figure 5 Role of the administration of nuclear factor kappa B (NF-kB)
oligonucleotide-loaded gelatin nanoparticles (D-NPs) in liver injury after
challenge with concanavalin A (ConA). Plasma levels of alanine
aminotransferase (ALT) and aspartate transaminase (AST) of mice
subjected to 7 h of ConA challenge (n = 3, mean with the SEM,
*p,0.05 vs scramble D-NPs).
Hepatology
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significant reduction in NF-kB binding activity (4.48 (SD 1.13)
vs 10.15 (SD 0.12) x-fold increase, ie, reduction to 44.1%; fig 3C).
The TNFa concentration in plasma was decreased and a
pronounced reduction of interleukin 6 (IL6) plasma concentra-
tion was observed in animals, which had received NF-kB
D-NPs (fig 3D).
Oligonucleotide-loaded gelatin nanoparticles attenuate pro-
apoptotic liver signalling
The jun N-terminal kinase (JNK) plays a major role in the
initiation of apoptotic pathways. Cross-talk between JNK and
NF-kB has been postulated before.27 Most strikingly, inhibition
of NF-kB in KCs led to a reduction in JNK phosphorylation
(fig 4A). In contrast, anti-apoptotic proteins such as X-linked
inhibitor of apoptosis protein (XIAP) or Bcl-xl remained
unchanged or even increased, respectively, as shown in fig 4B.
In line with these effects caspase-3 activity in liver tissue was
markedly decreased (fig 4C).
NF-kB oligonucleotide-loaded gelatin nanoparticles reduce injury
in the concanavalin a model of hepatitis
For LPS challenge circulating TNFa is relevant,28 we therefore
investigated the effects of D-NPs also in the ConA induced liver
Figure 6 Impact of nuclear factor kappa
B (NF-kB) inhibition on hepatic
ischaemia–reperfusion injury (IRI). (A)
NF-kB binding activity was determined
by electromobility shift assay (EMSA) of
whole rat liver homogenates after 1 h of
warm ischaemia and 2 h of reperfusion.
One representative shift is shown (upper
panel). Lower panel shows the relative
light unit (RLU) density. Controls were
defined as 1.0 (n = 3, mean with the
SEM, *p,0.05 vs scr. (scramble) D-NPs).
(B) Transaminase levels of rats subjected
to 1 h of ischaemia and 24 h of warm
reperfusion (n = 4, mean with the SEM,
*p,0.05 vs D-NPs). (C) Plasma tumour
necrosis factor a (TNFa) levels of rats
subjected to 1 h of warm ischaemia and
24 h of reperfusion (n = 4, mean with the
SEM). ALT, alanine aminotransferase;
AST, aspartate transaminase;
D-NPs, oligonucleotide-loaded gelatin
nanoparticles.
Table 1 Histological analysis of liver tissue
Decoy
nanoparticles
Scrambled decoy
nanoparticles
Necrosis (% of area) 63.75 (17) 40 (4)
Leucocytes (per 10 high-power fields) 394 (56) 260 (116)
TUNEL-positive cells (per 20 high-power
fields)
11 (1) 12 (2)
Data are mean (SEM).
Hepatology
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damage which is mainly mediated by cell-bound TNFa.
Interestingly NF-kB D-NPs abrogated ConA-induced liver
damage as well (fig 5).
Impact of NF-kB oligonucleotide-loaded gelatin nanoparticles on
hepatic ischaemia–reperfusion injury
Hepatic ischaemia occurs during liver resections or transplanta-
tions. It is assumed that NF-kB is activated in KCs soon upon
reperfusion. As yet the actual role of NF-kB in KCs in
ischaemia–reperfusion injury has not been addressed due to
the lack of a suitable experimental tool. Hence, we investigated
the impact of Kupffer cell targeted NF-kB for the outcome of
hepatic ischaemia–reperfusion injury by injecting D-NPs.
Interestingly, an inhibition of NF-kB binding activity (fig 6A)
led to an increase in liver injury after 24 h of reperfusion (fig 6B).
Measurement of plasma TNFa indicated no difference in TNFa
levels between the respective groups at 24 h reperfusion time
(fig 6C). Furthermore, histological analysis as described under
‘‘materials and methods’’ revealed that ischaemia–reperfusion
liver tissue of NF-kB D-NP-treated animals display a higher
proportion of centrilobular coagulative necrosis, as well as
stronger leucocyte infiltration, but no difference in TUNEL-
positive, apoptotic cells (table 1) compared to tissue of
scrambled D-NP-treated animals. Apoptosis was exclusively
evaluated in non-necrotic liver parenchyma because in the
necrosis an intense artificial staining of the hepatic cytoplasm
and nuclei occurred.
DISCUSSION
KCs play an important role in the pathogenesis of various
inflammatory liver diseases.29 Inhibition of Kupffer cell activity
by depletion with gadolinium chloride or clodronate liposomes
reduces liver damage after ischaemia/reperfusion and ConA
treatment, respectively.30–32 However, complete elimination
and permanent inactivation of this important cell type from
the liver is not a therapeutic option, since KCs are
indispensable for immune function.33 Thus, strategies aiming
at a reversible inhibition of KC-driven inflammatory signalling
such as NF-kB activation which might be clinically applicable
are an important goal. Here we present a novel approach of
selective KC targeting, which (1) might be of potential clinical
use and (2) was appropriate to elucidate the role of NF-kB in
KCs in various types of acute liver injury and ischaemia–
reperfusion injury.
In a model of fulminant liver failure (GalN/LPS), a disease
that is associated with many complications and high mortality
in the clinic, administration of KC-targeting NF-kB D-NPs
indeed resulted in a marked reduction of liver injury.
Hepatocyte-specific NF-kB inhibition is associated with a
TNFa induced increase of apoptosis and mortality.5 7 Kupffer
cell selective downregulation of NF-kB by D-NPs, as shown
here, leads to decreased inflammatory cytokine release as well as
reduced apoptotic activity and tissue damage after GalN/LPS
challenge. Along this line, phosphorylation and consecutively
activation of the pro-apoptotic kinase JNK was blocked. This is
in contrast to reports of NF-kB inhibition leading to prolonged
JNK activation.4 27 However, it has to be noted that these
observations were made in hepatocytes. Obviously a selective
inhibition of NF-kB in KCs leads to a reduction of parenchymal
tissue injury in the liver, since the attenuation of TNFa
production by KCs is most likely associated with lower JNK
activity in hepatocytes and thus apoptotic activity as deter-
mined by caspase-3 activity. Selective inhibition of NF-kB in
KCs did not impair XIAP expression, and even increased anti-
apoptotic Bcl-xl protein levels, both driven by NF-kB activity,
furthermore pointing to the fact that hepatocyte signalling was
not immediately affected by D-NPs. In contrast, anti-apoptotic
signalling in hepatocyte-specific NF-kB deficient mice presented
by Beraza et al5 and Geisler et al.7 is reduced, which might
explain the worsening of liver injury in their models.
Recent data34 show a marked increase in liver damage after
GalN/LPS challenge, if NF-kB activity is reduced by the general
NF-kB inhibitor pyrrolidene dithiocarbamate (PDTC), which
blocks NF-kB activation in both KCs and hepatocytes.
Hepatic ischaemia/reperfusion injury is another setting where
inflammatory processes are thought to be responsible for tissue
damage. KCs react fast after the onset of the reperfusion period
and produce large amounts of reactive oxygen species (ROS),
which subsequently trigger production and release of NF-kB
driven cytokines like TNFa and IL6.35 Thus, a selective NF-kB
inhibition in KCs should result in a similar beneficial outcome as
seen in the model of GalN/LPS induced liver injury. For
instance, Lentsch and colleagues showed recently that higher
NF-kB levels in hepatocytes during ischaemia–reperfusion are
linked with protection, while an increase of NF-kB in KCs rather
induces TNFa release and liver damage.36 Surprisingly, applica-
tion of D-NPs and thus Kupffer cell specific NF-kB inhibition
increased hepatic damage even further. This is in contrast to
Matsui et al, who described less liver injury by treatment with
PDTC in a model of 1 h warm ischaemia and 24 h of
reperfusion.37 This again supports the notion that an overall
inhibition of NF-kB with PDTC, in comparison to a selective
NF-kB blockade in KCs, leads to opposite effects. Moreover,
PDTC acts as a radical scavenger and exerts mainly anti-
oxidative properties,38 which makes its use as selective NF-kB
inhibitor rather questionable.
In conclusion, we here present a novel tool to selectively inhibit
NF-kB in KCs in vivo. We examined the impact of this selective
NF-kB inhibition in the inflammatory models of GalN/LPS and
ConA challenge, respectively, as well as in hepatic ischaemia–
reperfusion injury. It turned out that NF-kB in KCs seems to be
indispensable for the protection of the hepatic parenchyma after
ischaemia–reperfusion, while a selective inhibition in KCs after
GalN/LPS or ConA challenge results in protection of the liver.
Interestingly, the inflammatory impact caused by Kupffer cell-
dependent NF-kB-activation during ischaemia–reperfusion seems
not to be predominant for tissue injury. In contrast, selective
inhibition in KCs leads to an increase in hepatic injury. Therefore,
treatments aiming at NF-kB in the liver have to be used carefully,
as effects specific to the type of cell and to the type of injury have
to be taken into account.
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